department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

EVEROLIMUS · pharmadog

pharmadog
drugs
EVEROLIMUS

drug

patient view →

EVEROLIMUS

Marketedupdated 2mo ago

by Novugen Pharma (Malaysia) Sdn Bhd

Approved

community read0 votes

all catalysts(6)

approval · 6

EVEROLIMUS — FDA approval

EVEROLIMUS — FDA approval

EVEROLIMUS — FDA approval

EVEROLIMUS — FDA approval

EVEROLIMUS — FDA approval

EVEROLIMUS — FDA approval

News(0)

no news has mentioned this drug yet

brand

EVEROLIMUS

generic

EVEROLIMUS

indication

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 1, 2028

~2.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Jul 1, 2028method-of-use (U-1681)US 90062242.0y
Jul 1, 2028method-of-use (U-1681)US 90062242.0y
Jul 1, 2028method-of-use (U-1681)US 90062242.0y
Jul 1, 2028method-of-use (U-1681)US 90062242.0y
May 1, 2026patentUS 8410131*PED
May 1, 2026patentUS 8410131*PED
May 1, 2026patentUS 8410131*PED
May 1, 2026patentUS 8410131*PED
Nov 1, 2025method-of-use (U-1368)US 8410131
Nov 1, 2025method-of-use (U-1368)US 8410131
Nov 1, 2025method-of-use (U-1368)US 8410131
Nov 1, 2025method-of-use (U-1368)US 8410131

Data sources

openFDA · ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

drugeverolimus SR36 co-mentions · 24 sources
drugeverolimus ODT36 co-mentions · 24 sources
drugZortress36 co-mentions · 24 sources
tagApproval16 co-mentions · 8 sources
tagAdCom15 co-mentions · 11 sources
tagPMA Approval15 co-mentions · 11 sources
tagSmall Molecule8 co-mentions · 8 sources
companyPar Pharmaceutical Inc5 co-mentions · 5 sources

Trials studying EVEROLIMUS

—REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemianot yet recruitingn=400
phase2Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Canceractive not recruitingn=435
phase4A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)active not recruitingn=4
phase2Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantrecruitingn=120
phase2Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)recruitingn=120
phase3Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.recruitingn=170
phase3Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)recruitingn=450
phase3Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumorsrecruitingn=298

more trials →